As diabetes treatment progresses, there are a number of new insulin and insulin-like products available on the market. To learn more about Fiasp and Humalog and decide which may be right for you, please read on.
What is Fiasp?
Fiasp is an injectable prescription medication, supplied ready-for-use. It is used to improve blood glucose levels in adults with both Type 1 and Type 2 diabetes. Rapid-acting, it enters the bloodstream about 2.5 minutes after injection.
Flexible and accessible, this medication can be administered right at the start of a meal or up to 20 minutes after beginning to eat. Fiasp is proven to help lower A1C levels (an important marker of diabetic condition) when it’s taken alongside a more traditional, longer-lasting insulin.
What is Humalog?
Humalog (known generically as insulin lispro) is a fast-acting type of therapeutic insulin that is administered via injection and beings acting within approximately 15 minutes. The efficacy profile of Humalog peaks about 1 hour following dosage and it generally continues working for 2 to 4 hours post-administration by injection.
Humalog is generally used to improve blood sugar levels – in both adults and children – who suffer from diabetes mellitus.
Differences between Fiasp and Humalog
The main difference between these two popular diabetes medications is their activity of onset, peak, and duration. Fiasp is more suitable for providing patients with an increased level of control over when the dose is administered. As a second option, Humalog may be appropriate if a longer-lasting insulin effect is required.
Any patient wishing to embark on a treatment regimen with either of these drugs should consult closely with their prescribing physician before making a decision about which medication is more appropriate.
